San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug marketplace in February after revealing promising details from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the company u